Glenmark settles patent case with Daiichi, Genzyme

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Magnetic Particles Steer the Vesicles for Drug Delivery

Researchers have gone on to demonstrate that microscopic drug...

AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D

AstraZeneca announces $50 billion of investment in the United...

UK government, Manufacturing, Investment, Clinical trials

The UK government will improve manufacturing and commercialisation as...

AI in Alzheimer Drug Development to Enhances Clinical Trials

Scientists applied artificial intelligence (AI) to reanalyse a clinical...

Glenmark Pharmaceuticals has settled patent litigation suit with Daiichi Sankyo and Genzyme in relation to its type-2 diabetes treatment Colesevelam Hydrochloride’s abbreviated new drug application (ANDA).

With this settlement, Glenmark can roll out its generic Colesevelam Hydrochloride products on 02 April 2015 or earlier under certain circumstances.

At present Daiichi Sankyo markets the drug in powder and tablet forms to treat primary hyperlipidemia and type 2 diabetes mellitus.

Late last year, Daiichi Sankyo and Genzyme filed a patent infringement case in the US District Court for the District of Delaware to stop the India-based pharma firm from selling its ANDA prior to expiration.

Latest stories

Related stories

Magnetic Particles Steer the Vesicles for Drug Delivery

Researchers have gone on to demonstrate that microscopic drug...

AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D

AstraZeneca announces $50 billion of investment in the United...

UK government, Manufacturing, Investment, Clinical trials

The UK government will improve manufacturing and commercialisation as...

AI in Alzheimer Drug Development to Enhances Clinical Trials

Scientists applied artificial intelligence (AI) to reanalyse a clinical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back